Clinical features and immune mechanisms directly linked to the altered liver function in patients with rheumatoid arthritis
Copyright © 2023. Published by Elsevier B.V..
BACKGROUND: The aim of this study was to explore the impact of arthritis on liver function using different approaches in vivo and in vitro.
METHODS: A cross-sectional study was performed on 330 non-obese/non-T2DM subjects: 180 RA patients, 50 NAFLD non-RA patients, and 100 healthy donors (HDs). A longitudinal study was conducted on 50 RA patients treated with methotrexate for six months. Clinical and laboratory parameters and markers of liver disease were collected. Mechanistic studies were carried out in both the CIA mouse model and hepatocytes treated with anti-citrullinated protein antibodies (ACPAs).
RESULTS: RA patients have an increased risk of suffering from liver disease independent of obesity or T2DM. This risk was associated with factors such as insulin resistance, autoantibodies, inflammation, and component C3. Methotrexate treatment for six months was associated with liver abnormalities in those newly-diagnosed patients having CV risk factors. ACPAs induced a defective hepatocyte function, promoting IR and inflammation. The induction of arthritis in mice caused the infiltration of immune cells in the liver and increased inflammatory, apoptotic, and fibrotic processes.
CONCLUSION: RA patients may experience mild to moderate liver inflammation due to the infiltration of T, B cells, and macrophages, and the action of ACPAs. This is independent of obesity or diabetes and linked to systemic inflammation, and disease activity levels. The negative effects of methotrexate on liver function could be restricted to the concomitant presence of cardiovascular risk factors.
| Errataetall: |
CommentIn: Eur J Intern Med. 2023 Dec;118:41-42. - PMID 37872035 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:118 |
|---|---|
| Enthalten in: |
European journal of internal medicine - 118(2023) vom: 04. Dez., Seite 49-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arias-de la Rosa, I [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
102338-89-6 |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 28.12.2023 published: Print-Electronic CommentIn: Eur J Intern Med. 2023 Dec;118:41-42. - PMID 37872035 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejim.2023.08.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360445225 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360445225 | ||
| 003 | DE-627 | ||
| 005 | 20231229124125.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejim.2023.08.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1241.xml |
| 035 | |a (DE-627)NLM360445225 | ||
| 035 | |a (NLM)37544847 | ||
| 035 | |a (PII)S0953-6205(23)00285-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arias-de la Rosa, I |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical features and immune mechanisms directly linked to the altered liver function in patients with rheumatoid arthritis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 28.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Eur J Intern Med. 2023 Dec;118:41-42. - PMID 37872035 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: The aim of this study was to explore the impact of arthritis on liver function using different approaches in vivo and in vitro | ||
| 520 | |a METHODS: A cross-sectional study was performed on 330 non-obese/non-T2DM subjects: 180 RA patients, 50 NAFLD non-RA patients, and 100 healthy donors (HDs). A longitudinal study was conducted on 50 RA patients treated with methotrexate for six months. Clinical and laboratory parameters and markers of liver disease were collected. Mechanistic studies were carried out in both the CIA mouse model and hepatocytes treated with anti-citrullinated protein antibodies (ACPAs) | ||
| 520 | |a RESULTS: RA patients have an increased risk of suffering from liver disease independent of obesity or T2DM. This risk was associated with factors such as insulin resistance, autoantibodies, inflammation, and component C3. Methotrexate treatment for six months was associated with liver abnormalities in those newly-diagnosed patients having CV risk factors. ACPAs induced a defective hepatocyte function, promoting IR and inflammation. The induction of arthritis in mice caused the infiltration of immune cells in the liver and increased inflammatory, apoptotic, and fibrotic processes | ||
| 520 | |a CONCLUSION: RA patients may experience mild to moderate liver inflammation due to the infiltration of T, B cells, and macrophages, and the action of ACPAs. This is independent of obesity or diabetes and linked to systemic inflammation, and disease activity levels. The negative effects of methotrexate on liver function could be restricted to the concomitant presence of cardiovascular risk factors | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ACPAs | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Liver disease risk | |
| 650 | 4 | |a NAFLD | |
| 650 | 4 | |a Proximity extension assay | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 7 | |a acetyl 4-aminosalicylic acid |2 NLM | |
| 650 | 7 | |a 102338-89-6 |2 NLM | |
| 650 | 7 | |a Methotrexate |2 NLM | |
| 650 | 7 | |a YL5FZ2Y5U1 |2 NLM | |
| 650 | 7 | |a Peptides, Cyclic |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 700 | 1 | |a Ruiz-Ponce, M |e verfasserin |4 aut | |
| 700 | 1 | |a Cuesta-López, L |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Sánchez, C |e verfasserin |4 aut | |
| 700 | 1 | |a Leiva-Cepas, F |e verfasserin |4 aut | |
| 700 | 1 | |a Gahete, M D |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro, P |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega, R |e verfasserin |4 aut | |
| 700 | 1 | |a Cordoba, J |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Pampin, E |e verfasserin |4 aut | |
| 700 | 1 | |a González, A |e verfasserin |4 aut | |
| 700 | 1 | |a Lucendo, A J |e verfasserin |4 aut | |
| 700 | 1 | |a Collantes-Estévez, E |e verfasserin |4 aut | |
| 700 | 1 | |a López-Pedrera, Ch |e verfasserin |4 aut | |
| 700 | 1 | |a Escudero-Contreras, A |e verfasserin |4 aut | |
| 700 | 1 | |a Barbarroja, N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of internal medicine |d 1997 |g 118(2023) vom: 04. Dez., Seite 49-58 |w (DE-627)NLM089689097 |x 1879-0828 |7 nnns |
| 773 | 1 | 8 | |g volume:118 |g year:2023 |g day:04 |g month:12 |g pages:49-58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejim.2023.08.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 118 |j 2023 |b 04 |c 12 |h 49-58 | ||